Migdady Yazan, Salhab Mohammed, Dang Nam H, Markham Merry J, Olszewski Adam J
a Department of Medicine , University of Florida , Gainesville , FL , USA ;
b University of Massachusetts Medical School , Worcester , MA , USA ;
Leuk Lymphoma. 2016;57(3):676-84. doi: 10.3109/10428194.2015.1102246. Epub 2015 Dec 23.
We evaluated the association of baseline prognostic factors with conditional net survival among survivors of six subtypes non-Hodgkin lymphoma using the SEER program data from 2000-2012. Among 2-year survivors, further prognosis markedly improved in Burkitt's (BL) and diffuse large B-cell lymphoma (DLBCL), and became the same as for follicular lymphoma (5-year net survival ≥ 85%). Mantle cell lymphoma (MCL) demonstrated the worst prognosis of all studied histologies up to 5 years of survivorship. Age and stage lost prognostic significance in BL within 2 years from diagnosis. Racial disparities in net survival disappeared within 2 years for all subtypes, except in chronic lymphocytic leukemia, where black patients had persistently worse prognosis, and in MCL, where they had unexpectedly better prognosis than other races after 2 years. Many baseline factors may lose their initial prognostic value for lymphoma survivors, which should be considered when counseling patients about their prognosis and long-term surveillance.
我们使用2000 - 2012年监测、流行病学和最终结果（SEER）项目的数据，评估了六种非霍奇金淋巴瘤亚型幸存者的基线预后因素与条件净生存之间的关联。在2年幸存者中，伯基特淋巴瘤（BL）和弥漫性大B细胞淋巴瘤（DLBCL）的进一步预后显著改善，与滤泡性淋巴瘤相同（5年净生存≥85%）。套细胞淋巴瘤（MCL）在所有研究组织学类型中，直至生存5年时预后最差。在诊断后2年内，年龄和分期在BL中失去了预后意义。除慢性淋巴细胞白血病（黑人患者预后持续较差）和MCL（2年后黑人患者预后意外好于其他种族）外，所有亚型的净生存种族差异在2年内消失。许多基线因素可能会失去其对淋巴瘤幸存者最初的预后价值，在为患者提供预后咨询和长期监测时应予以考虑。
